S 164
117th Congress
Senate
Health
Drug safety, medical device, and laboratory regulation
Government information and archives
Health personnel
Licensing and registrations
Medical education
Prescription drugs
Advancing Education on Biosimilars Act of 2021
Introduced: February 2, 2021
Introduced by:
Hassan, Margaret Wood
Democratic
· New Hampshire
See on congress.gov
Everywhere this bill has been
20 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 23, 2021
Became Public Law No: 117-8.
Apr 23, 2021
Signed by President.
Apr 20, 2021
Presented to President.
Apr 14, 2021
Motion to reconsider laid on the table Agreed to without objection.
Apr 14, 2021
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101). (text: CR H1754)
Apr 14, 2021
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101).(text: CR H1754)
Apr 14, 2021
Considered as unfinished business. (consideration: CR H1783-1784)
Apr 14, 2021
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Apr 14, 2021
DEBATE - The House proceeded with forty minutes of debate on S. 164.
Apr 14, 2021
Considered under suspension of the rules. (consideration: CR H1754-1755)
Apr 14, 2021
Mr. Pallone moved to suspend the rules and pass the bill.
Mar 8, 2021
Held at the desk.
Mar 8, 2021
Received in the House.
Mar 8, 2021
Message on Senate action sent to the House.
Mar 3, 2021
Passed Senate without amendment by Unanimous Consent. (text: CR S1021)
Mar 3, 2021
Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S1021)
Mar 3, 2021
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S1021)
Mar 3, 2021
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S1021)
Feb 2, 2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Feb 2, 2021
Introduced in Senate
Votes taken on this bill
1
| Date | Chamber | What was voted on | Result | Yes–No | |
|---|---|---|---|---|---|
| Apr 14, 2021 | House · vote #101 | On Motion to Suspend the Rules and Pass | Passed | 412–8 | See who voted → |
Plain-English summary
Advancing Education on Biosimilars Act of 2021
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
The FDA may also maintain and operate a website to provide educational materials about biological products.
What's happening now
Became Public Law No: 117-8.
Committees of jurisdiction
1
Cosponsors
1